Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

APRIL promotes B-1 cell-associated neoplasm.

Lourdes Planelles1, Carla E Carvalho-Pinto, Gijs Hardenberg

  • 1Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, UAM Campus Cantoblanco, E-28049 Madrid, Spain.

Cancer Cell
|October 19, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Necroptotic cell death and immunomodulator release induced by T-cell engaging anti-lymphoma therapies.

Cell death & disease·2026
Same author

Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root Causes.

Kidney international reports·2026
Same author

Imbalances of mitochondrial dynamics in solid tumors.

Oncogenesis·2026
Same author

IL21-STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemia.

HemaSphere·2026
Same author

Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment.

Cancer research·2025
Same author

Mesenchymal Colorectal Cancers Secrete Vesicles With Unique Cargo That Can Be Used for Liquid Biopsy Based Diagnostics.

Journal of extracellular vesicles·2025

Tumor necrosis factor ligand superfamily member 13B (APRIL) promotes lymphoid tumors in mice. Increased APRIL levels in B cell chronic lymphoid leukemia (B-CLL) patients suggest APRIL antagonism as a potential therapy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The TNF-like ligand APRIL is implicated in supporting tumor development.
  • B-1 B cells are a key component of the peritoneal immune system.

Purpose of the Study:

  • To investigate the role of APRIL in lymphoid tumor formation.
  • To explore the potential of APRIL antagonism as a therapeutic strategy for B cell chronic lymphoid leukemia (B-CLL).

Main Methods:

  • Generation and analysis of APRIL transgenic mice.
  • Histopathological examination of lymphoid tissues and non-lymphoid organs.
  • Quantification of APRIL levels in patient sera.

Main Results:

  • APRIL transgenic mice aged 9-12 months developed lymphoid tumors originating from peritoneal B-1 B cells.

Related Experiment Videos

  • Tumors showed progressive hyperplasia, tissue disorganization, infiltration, and metastasis to kidney and liver.
  • Elevated APRIL serum levels were observed in B-CLL patients.

    • Conclusions:

    • APRIL actively promotes the development of B-1 B cell-associated neoplasms.
    • Targeting APRIL may represent a viable therapeutic approach for B-CLL.